You can buy or sell ADAP and other stocks, options, ETFs, and crypto commission-free!
Adaptimmune Therapeutics plc American Depositary Shares, also called Adaptimmune Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Read More The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
52 Week High
52 Week Low
Seeking AlphaMay 15
Adaptimmune teams up with Alpine to develop next-gen cell therapies
Adaptimmune (ADAP +3.7% ) will collaborate with Alpine Immune Sciences (ALPN +4.4% ) to develop next-generation SPEAR T-cell products based on the latter's secreted and transmembrane immunomodulatory protein (SIP and TIP) technology.
Yahoo FinanceMay 9
Here’s What Hedge Funds Think About Adaptimmune Therapeutics plc
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from peak to trough.
-$0.31 per share
-$0.04 per share